ECSP20080995A - Derivados de tetrahidrotienopiridina nsustituidos y sus usos - Google Patents
Derivados de tetrahidrotienopiridina nsustituidos y sus usosInfo
- Publication number
- ECSP20080995A ECSP20080995A ECSENADI202080995A ECDI202080995A ECSP20080995A EC SP20080995 A ECSP20080995 A EC SP20080995A EC SENADI202080995 A ECSENADI202080995 A EC SENADI202080995A EC DI202080995 A ECDI202080995 A EC DI202080995A EC SP20080995 A ECSP20080995 A EC SP20080995A
- Authority
- EC
- Ecuador
- Prior art keywords
- substituted
- tetrahydrothienopyridine derivatives
- derivatives
- substituted tetrahydrothienopyridine
- useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proporciona un compuesto de Fórmula (I) que ha demostrado ser útil para el tratamiento de una enfermedad causada por una infección viral:(I) en donde R1, R2, R3, A, L, m, n, p y q son como se definen en la presente memoria.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862687068P | 2018-06-19 | 2018-06-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP20080995A true ECSP20080995A (es) | 2021-02-26 |
Family
ID=67841114
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSENADI202080995A ECSP20080995A (es) | 2018-06-19 | 2020-12-15 | Derivados de tetrahidrotienopiridina nsustituidos y sus usos |
Country Status (23)
Country | Link |
---|---|
US (1) | US20220073535A1 (es) |
EP (2) | EP4169925A3 (es) |
JP (1) | JP7328260B2 (es) |
KR (1) | KR20210022645A (es) |
CN (1) | CN112313237A (es) |
AU (1) | AU2019291488B2 (es) |
BR (1) | BR112020025696A2 (es) |
CA (1) | CA3100957A1 (es) |
CL (1) | CL2020003248A1 (es) |
CR (1) | CR20200618A (es) |
CU (1) | CU20200100A7 (es) |
EA (1) | EA202190046A1 (es) |
EC (1) | ECSP20080995A (es) |
ES (1) | ES2941946T3 (es) |
IL (1) | IL279441B2 (es) |
JO (1) | JOP20200326A1 (es) |
MA (1) | MA52976A (es) |
MX (1) | MX2020013852A (es) |
PE (1) | PE20210097A1 (es) |
PH (1) | PH12020552185A1 (es) |
SA (1) | SA520420809B1 (es) |
SG (1) | SG11202012625PA (es) |
WO (1) | WO2019244047A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019024809A1 (zh) * | 2017-08-01 | 2019-02-07 | 正大天晴药业集团股份有限公司 | 作为RORγ抑制剂的双环化合物 |
USD1006154S1 (en) * | 2023-06-27 | 2023-11-28 | Qiongfang Mao | Cable crossover attachment |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US498178A (en) | 1893-05-23 | William valentine leonard | ||
US54472A (en) | 1866-05-01 | Improved blacking-brush | ||
US6344A (en) | 1849-04-17 | Driving-bobbin | ||
US8766A (en) | 1852-02-24 | Appabatus for lightening vessels | ||
US4656A (en) | 1846-07-24 | Improvement in potato-plows | ||
US5807A (en) | 1848-09-26 | Brake fob cabs | ||
US5807876A (en) | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
AU723730B2 (en) | 1996-04-23 | 2000-09-07 | Vertex Pharmaceuticals Incorporated | Urea derivatives as inhibitors of IMPDH enzyme |
ATE244717T1 (de) | 1997-03-14 | 2003-07-15 | Vertex Pharma | Inhibitoren des impdh-enzyms |
AR029341A1 (es) | 1999-03-19 | 2003-06-25 | Vertex Pharma | Inhibidores de la enzima impdh (inosina-5'-monofosfato dehidrogenasa) |
US7138529B2 (en) * | 2003-04-16 | 2006-11-21 | Hoffmann-La Roche Inc. | Substituted 3-cyanothiophene acetamides as glucagon receptor antagonists |
AP3069A (en) | 2009-02-27 | 2014-12-31 | Siga Technologies Inc | Thienopyridine derivatives for the treatment and prvention of dengue virus infection |
US20130129677A1 (en) * | 2009-02-27 | 2013-05-23 | Siga Technologies, Inc. | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections |
JP5701655B2 (ja) | 2011-03-29 | 2015-04-15 | 奈良県 | 植物精油中のトロポロン類及び/又はフェノール類の金属錯体化方法 |
CN108689987A (zh) * | 2017-04-05 | 2018-10-23 | 浙江海正药业股份有限公司 | 一种磺胺类衍生物及其制备方法和用途 |
CR20190531A (es) * | 2017-05-22 | 2020-03-05 | Janssen Pharmaceuticals Inc | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue |
CN108191885B (zh) * | 2018-01-29 | 2020-08-04 | 华东师范大学 | 一类哌啶并噻吩类小分子有机化合物及其应用 |
-
2019
- 2019-06-18 ES ES19762467T patent/ES2941946T3/es active Active
- 2019-06-18 MA MA052976A patent/MA52976A/fr unknown
- 2019-06-18 CR CR20200618A patent/CR20200618A/es unknown
- 2019-06-18 EA EA202190046A patent/EA202190046A1/ru unknown
- 2019-06-18 JO JOP/2020/0326A patent/JOP20200326A1/ar unknown
- 2019-06-18 SG SG11202012625PA patent/SG11202012625PA/en unknown
- 2019-06-18 JP JP2020570065A patent/JP7328260B2/ja active Active
- 2019-06-18 MX MX2020013852A patent/MX2020013852A/es unknown
- 2019-06-18 WO PCT/IB2019/055121 patent/WO2019244047A1/en unknown
- 2019-06-18 CN CN201980040348.4A patent/CN112313237A/zh active Pending
- 2019-06-18 PE PE2020002060A patent/PE20210097A1/es unknown
- 2019-06-18 US US17/253,755 patent/US20220073535A1/en active Pending
- 2019-06-18 EP EP22207844.6A patent/EP4169925A3/en active Pending
- 2019-06-18 EP EP19762467.9A patent/EP3810613B1/en active Active
- 2019-06-18 KR KR1020217001077A patent/KR20210022645A/ko unknown
- 2019-06-18 BR BR112020025696-0A patent/BR112020025696A2/pt unknown
- 2019-06-18 AU AU2019291488A patent/AU2019291488B2/en active Active
- 2019-06-18 CA CA3100957A patent/CA3100957A1/en active Pending
- 2019-06-18 CU CU2020000100A patent/CU20200100A7/es unknown
-
2020
- 2020-12-14 IL IL279441A patent/IL279441B2/en unknown
- 2020-12-15 SA SA520420809A patent/SA520420809B1/ar unknown
- 2020-12-15 EC ECSENADI202080995A patent/ECSP20080995A/es unknown
- 2020-12-15 CL CL2020003248A patent/CL2020003248A1/es unknown
- 2020-12-16 PH PH12020552185A patent/PH12020552185A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20220073535A1 (en) | 2022-03-10 |
PH12020552185A1 (en) | 2021-06-07 |
EP4169925A3 (en) | 2023-06-14 |
JP7328260B2 (ja) | 2023-08-16 |
CR20200618A (es) | 2021-01-21 |
JOP20200326A1 (ar) | 2020-12-14 |
SG11202012625PA (en) | 2021-01-28 |
CN112313237A (zh) | 2021-02-02 |
PE20210097A1 (es) | 2021-01-12 |
IL279441A (en) | 2021-01-31 |
SA520420809B1 (ar) | 2022-08-17 |
AU2019291488A1 (en) | 2021-02-04 |
CL2020003248A1 (es) | 2021-07-09 |
WO2019244047A1 (en) | 2019-12-26 |
IL279441B2 (en) | 2023-06-01 |
EP4169925A2 (en) | 2023-04-26 |
BR112020025696A2 (pt) | 2021-03-16 |
CU20200100A7 (es) | 2021-08-06 |
KR20210022645A (ko) | 2021-03-03 |
EA202190046A1 (ru) | 2021-03-24 |
EP3810613A1 (en) | 2021-04-28 |
ES2941946T3 (es) | 2023-05-26 |
EP3810613B1 (en) | 2023-01-11 |
MA52976A (fr) | 2021-04-28 |
AU2019291488B2 (en) | 2022-02-24 |
CA3100957A1 (en) | 2019-12-26 |
JP2021529159A (ja) | 2021-10-28 |
MX2020013852A (es) | 2021-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY35155A (es) | Derivados cíclicos de nucleósidos y usos de los mismos | |
DOP2017000149A (es) | Compuestos de triazolopirimidina y usos de los mismos | |
CO2019000932A2 (es) | Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica. | |
CL2019000271A1 (es) | Inhibidores de polimerasa hcv. (divisional solicitud 201600493) | |
CO2017007355A2 (es) | Compuestos derivados de pirazincarbozamida y de pirazincarboxilato para el tratamiento de la infección por el virus de hepatitis b | |
ECSP15018618A (es) | Inhibidores no nucleósidos de la transcriptasa inversa | |
CU24605B1 (es) | Pirimidin-2-il amino-1h-pirazoles útiles como inhibidores de lrrk2 | |
DOP2019000140A (es) | Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih | |
CY1125004T1 (el) | Ετεροαρυλο υποκατεστημενες βητα-υδροξυαιθυλαμινες για χρηση στη θεραπεια της υπεργλυκαιμιας | |
CO6341623A2 (es) | Compuestos organicos | |
CO2017009994A2 (es) | Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas | |
UY37774A (es) | Compuestos 5-cianoindol sustituidos y usos de los mismos | |
ECSP17007336A (es) | Compuestos de imidazopiridazina | |
DOP2016000308A (es) | Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer | |
ECSP20080995A (es) | Derivados de tetrahidrotienopiridina nsustituidos y sus usos | |
CO2020010306A2 (es) | Compuestos de sulfonimidoilpurinona 7-sustituida y derivados para el tratamiento y profilaxis de cáncer de hígado. | |
UY37641A (es) | Compuestos de isoxazol carboxamida y usos de los mismos | |
DOP2013000051A (es) | Compuestos heterociclico y sus usos | |
CR20180615A (es) | Nuevos derivados de [1,2,3]triazol[4,5-d]pirimidina | |
TR201910158T4 (tr) | İmmün hastalıklara yönelik önleyici ve/veya terapötik ajan. | |
CR20170261A (es) | Ácido 3-(6-alcoxi-5-clorbenzo[d]isoxazol-3-il)propanoico útil como inhubidores de quinurenina monooxigenasa | |
DOP2019000102A (es) | Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus | |
UY35627A (es) | Derivados de 2-((2s,3s,4r,5r)-5-((s)-3-amino-2-hidroxiprop-1-il)-4-metoxi-3-(fenilsulfonilmetil)tetrahidrofuran-2-il)acetaldehido y procedimiento para su preparacion. |